Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Inclusion Criteria: * Patient must have been diagnosed with CML-CP at \< 18 years of age. * Patient must have histologic verification of CML-CP at original diagnosis * Patient must be in molecular remission (MR) with a BCR-ABL1 level of =\< 0.01% BCR-ABL1 as measured using the International Scale (IS) by RQ-PCR for \>= 2 consecutive years at the time of enrollment * Please note: The lab evaluating disease status and molecular response for this study must be College of American Pathology (CAP) and/or Clinical Laboratory Improvement Amendments (CLIA) certified (United States \[US\] only), sites in other countries must be certified by their accredited authorities. All labs must use the International Scale guidelines with a sensitivity of detection assay =\< 0.01% BCR-ABL1 and be able to report results in =\< 2 weeks * Patient must have received any TKI for a minimum of 3 consecutive years at time of enrollment * Patient agrees to discontinue TKI therapy * REGULATORY REQUIREMENTS * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met * ELIGIBILITY FOR PATIENT-REPORTED OUTCOMES (PROs): * Age \>= 8 years at the time of enrollment * Ability to understand English or Spanish * Cognitive ability to complete instruments according to the primary team * ELIGIBILITY FOR AAML18P1 NEUROCOGNITIVE STUDY: * Patient must …